Evidence map›Paper›PMID 35481438›Full record

ArticleBJPsych open2022

Cariprazine as a treatment for negative psychotic symptoms in first-episode psychosis: case series.

Arsime Demjaha, Eduardo Iacoponi, Lars Hansen, Pradeep Peddu, Philip McGuire

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BJPsych open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Observational
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Arsime DemjahaDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, UK; and NIHR Maudsley Biomedical Research Centre, South London and Maudsley NHS Foundation Trust and King's College London, UK.ORCID https://orcid.org/0000-0002-1870-6410
Eduardo IacoponiLambeth Early Intervention Service, South London and Maudsley NHS Foundation Trust, UK.
Lars HansenDepartment of Psychiatry, Southampton University, UK.
Pradeep PedduPsychosis Service, Coventry and Warwickshire Partnership NHS Trust, UK.
Philip McGuireDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, UK; and NIHR Maudsley Biomedical Research Centre, South London and Maudsley NHS Foundation Trust and King's College London, UK.ORCID https://orcid.org/0000-0003-4381-0532

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Negative psychotic symptoms are among the most disabling features of schizophrenia, and are strongly associated with relatively poor clinical and functional outcomes. However, there are no effective treatments for negative symptoms, and this represents a major unmet clinical need. Recent research has shown that negative symptoms are already present in many patients at illness onset. There is evidence that cariprazine may improve negative symptoms in patients with chronic schizophrenia. However, its utility in treating negative symptoms in the early stage of the disorder is unclear. Here, we report six cases of patients with first-episode psychosis who were treated with cariprazine.

Indexed as

antipsychoticscariprazinefirst-episode psychosisNegative symptomsnovel central nervous system drugs

Identifiers

PMID35481438
PMCPMC9059739

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.